UBS Group’s Orexigen Therapeutics, Inc. OREX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q2 | – | Sell |
-11,155
| Closed | -$3K | – | 8685 |
|
|
2018
Q1 | $3K | Buy |
11,155
+8,505
| +321% | +$7.84K | ﹤0.01% | 7504 |
|
|
2017
Q4 | $3K | Sell |
2,650
-60
| -2% | -$98 | ﹤0.01% | 7588 |
|
|
2017
Q3 | $6K | Sell |
2,710
-2,419
| -47% | -$5.9K | ﹤0.01% | 7194 |
|
|
2017
Q2 | $15K | Buy |
5,129
+46
| +0.9% | +$138 | ﹤0.01% | 6528 |
|
|
2017
Q1 | $17K | Buy |
5,083
+1,373
| +37% | +$5.42K | ﹤0.01% | 6296 |
|
|
2016
Q4 | $6K | Buy |
3,710
+100
| +3% | +$235 | ﹤0.01% | 7216 |
|
|
2016
Q3 | $12K | Buy |
3,610
+3,180
| +740% | +$12K | ﹤0.01% | 6702 |
|
|
2016
Q2 | $2K | Sell |
430
-190
| -31% | -$859 | ﹤0.01% | 7512 |
|
|
2016
Q1 | $3K | Hold |
620
| – | – | ﹤0.01% | 7275 |
|
|
2015
Q4 | $11K | Sell |
620
-3,183
| -84% | -$75.9K | ﹤0.01% | 7263 |
|
|
2015
Q3 | $80K | Buy |
3,803
+2,887
| +315% | +$98.9K | ﹤0.01% | 5417 |
|
|
2015
Q2 | $45K | Sell |
916
-330
| -26% | -$19.7K | ﹤0.01% | 6100 |
|
|
2015
Q1 | $98K | Buy |
1,246
+371
| +42% | +$23K | ﹤0.01% | 5438 |
|
|
2014
Q4 | $53K | Buy |
+875
| New | +$44K | ﹤0.01% | 6435 |
|
Other funds holding OREX
UBS Group's OREX Position: Q2 2018 in Review
UBS Group sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2018, closing a stake of 11,155 shares — an estimated $3K sold.
UBS Group first reported a position in OREX in Q4 2014 and held it in 14 quarters. The position peaked at $98K in Q1 2015. 4 funds tracked by Wall St. Rank hold OREX as of Q2 2018.
- UBS Group reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
- UBS Group sold 11,155 Orexigen Therapeutics, Inc. shares in Q2 2018, an estimated $3K.
- UBS Group first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and held it in 14 quarters.
- UBS Group's Orexigen Therapeutics, Inc. position peaked at $98K in Q1 2015.
- 4 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2018.
Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.